{"id":2226,"date":"2026-06-10T00:00:00","date_gmt":"2026-06-10T03:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2226"},"modified":"2026-06-10T00:00:00","modified_gmt":"2026-06-10T03:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-hepatica-hcc-cca-ressecao-tx-tace-y-90-sirt-atezo-bev","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-hepatica-hcc-cca-ressecao-tx-tace-y-90-sirt-atezo-bev\/","title":{"rendered":"PGRSS hep\u00e1tica: HCC, CCA, ressec, TACE, Y-90"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica hep\u00e1tica que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica hep\u00e1tica<\/strong> + HCC hepatocelular carcinoma cirrose+VHB+VHC+\u00e1lcool+NASH<\/strong> + iCCA intra-hepatic cholangiocarcinoma<\/strong> + ressec\u00e7\u00e3o hepatectomia anat\u00f4mica+n\u00e3o-anat\u00f4mica<\/strong> + TX hep\u00e1tico MELD score+UCSF+Milan crit\u00e9rios<\/strong> + TACE Trans-Arterial Chemoembolization DEB-TACE<\/strong> + Y-90 SIRT Selective Internal Radiation Therapy<\/strong> + atezolizumab+bevacizumab IMbrave150<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (HCC + iCCA + adenoCa metast\u00e1tico + GIST hep\u00e1tico raro + hepatoblastoma pedi\u00e1trico) + Grupo A4 (linfa hilar + porta hepatis + tronco cel\u00edaco + retroperitoneal) + Grupo C (Y-90 SIR-Spheres Sirtex+TheraSphere Boston Scientific + Iridium-192 raro) + Grupo E (perfuro bi\u00f3psia + agulha core ultrassom-guiada + TIPS) + Lista C5 (atezolizumab Tecentriq + bevacizumab Avastin + lenvatinib Lenvima + sorafenib Nexavar + cabozantinib Cabometyx + durvalumab Imfinzi + tremelimumab Imjudo + nivolumab Opdivo + ipilimumab Yervoy + futibatinib Lytgobi + pemigatinib Pemazyre + ivosidenib Tibsovo). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + TACE\/Y-90<\/strong> + subdimensionam imuno IMbrave150<\/strong> + perdem rastreabilidade tumor hep\u00e1tico<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS hep\u00e1tica opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (HCC 80% + iCCA 10% + metast\u00e1tico 5% + outros 5%), A4 (linfadenectomia hilar+cel\u00edaca+retroperitoneal), C (Y-90 SIRT + Iridium raro), E (bi\u00f3psia + TIPS + abla\u00e7\u00e3o RF\/microwave), Lista C5 (atezo+bev IMbrave150 + lenvatinib REFLECT + sorafenib SHARP + cabozantinib CELESTIAL + durvalumab+tremelimumab HIMALAYA + futibatinib FGFR2 iCCA + pemigatinib + ivosidenib IDH1).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica hep\u00e1tica, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos hep\u00e1ticos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS hep\u00e1tica tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 HCC+iCCA<\/td>\n5-14 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCirrose+VHB\/VHC+NASH<\/td>\n<\/tr>\n
A4 hilar+porta<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nHepatoduodenal+cel\u00edaca<\/td>\n<\/tr>\n
C Y-90 SIRT<\/td>\n0,8-2,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nSIR+TheraSphere+CNEN<\/td>\n<\/tr>\n
E abla\u00e7\u00e3o RF+TIPS<\/td>\n0,8-2,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nRFA+microwave+TIPS<\/td>\n<\/tr>\n
Lista C5 imuno+TKI<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nAtezo+bev+lenv+cabo<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,1-32,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica hep\u00e1tica m\u00e9dia porte.<\/p>\n

A1 HCC + iCCA + cirrose subjacente: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS hep\u00e1tica \u00e9 A1. Padr\u00e3o setorial inclui (a) HCC hepatocelular 80%<\/strong> com cirrose subjacente 80-90% + VHB hepatite B + VHC hepatite C + \u00e1lcool + NASH non-alcoholic steatohepatitis + Child-Pugh A\/B\/C + AFP alfa-fetoprote\u00edna marcador; (b) iCCA intra-hepatic cholangiocarcinoma 10%<\/strong> com mass-forming + periductal infiltrating + intraductal growing + IDH1 muta\u00e7\u00e3o 15% + FGFR2 fusion 10-15% + KRAS+BRAF; (c) met\u00e1stase hep\u00e1tica 5%<\/strong> com colorretal mais comum + mama + neuroend\u00f3crino + melanoma + sarcoma + ressec\u00e7\u00e3o R0 + TACE + Y-90; (d) estadiamento BCLC Barcelona Clinic Liver Cancer<\/strong> com 0\/A potencialmente curativo + B intermedi\u00e1rio TACE + C avan\u00e7ado sist\u00eamico + D terminal paliativo; (e) descarte sub-fluxos<\/strong> com pr\u00e9-pesagem + saco branco leitoso + identifica\u00e7\u00e3o A1+SUBS\u00cdTIO+BCLC+CID C22 + lacre + rastreabilidade + Child-Pugh classifica\u00e7\u00e3o.<\/p>\n

Cl\u00ednica com A1 hep\u00e1tica madura garante margem R0<\/strong> + previne recidiva hep\u00e1tica<\/strong> + otimiza TX MELD score<\/strong>. Como discutimos no post sobre vias biliares<\/a>, A1 \u00e9 a base.<\/p>\n

A4 hepatectomia + TX hep\u00e1tico MELD + Milan: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) hepatectomia anat\u00f4mica<\/strong> com Couinaud segmentos I-VIII + segmentectomia + setorectomia + bissegmentectomia + lobectomia direita+esquerda + trisegmentectomia ampliada; (b) hepatectomia n\u00e3o-anat\u00f4mica<\/strong> com wedge resection + par\u00eanquima-poupador + ALPPS Associating Liver Partition with Portal Vein Ligation + 2-stage hepatectomia; (c) PVE Portal Vein Embolization<\/strong> com Onyx ev3 + PVA polyvinyl alcohol + cyanoacrylate + indu\u00e7\u00e3o hipertrofia FLR Future Liver Remnant 25-40% + 2-6 semanas; (d) TX hep\u00e1tico<\/strong> com Mayo Clinic protocol HCC Milan crit\u00e9rios 1 nodo \u22645cm ou 3 nodos \u22643cm + UCSF expanded 1 nodo \u22646,5cm ou 3 nodos \u22644,5cm soma \u22648cm + MELD score Model End-Stage Liver Disease + score 22 m\u00ednimo lista; (e) doador vivo<\/strong> RLDLT Right Lobe Living Donor Liver Transplantation + LLDLT Left Lobe + APOLT Auxiliary Partial Orthotopic + dual-graft.<\/p>\n

Cl\u00ednica com A4 hepatectomia+TX madura escala R0 70-90%<\/strong> + previne IPH insufici\u00eancia hep\u00e1tica p\u00f3s-op<\/strong> + otimiza sobrevida 5y TX 75%<\/strong>. Conex\u00e3o com hospital especializado<\/a>.<\/p>\n

TACE + Y-90 SIRT + abla\u00e7\u00e3o RF\/microwave + atezo+bev IMbrave150: o est\u00e1gio loco-regional+sist\u00eamico<\/h2>\n

A terceira camada \u00e9 TACE+Y-90+abla\u00e7\u00e3o+sist\u00eamico. Padr\u00e3o setorial inclui (a) TACE Trans-Arterial Chemoembolization<\/strong> com cTACE convencional Lipiodol+doxorrubicina + DEB-TACE drug-eluting beads DC Bead Boston\/HepaSphere Merit\/LC Bead Biocompatibles + doxorrubicina+irinotecan; (b) Y-90 SIRT Selective Internal Radiation Therapy<\/strong> com SIR-Spheres Sirtex resin + TheraSphere Boston Scientific glass + Y-90 yttrium-90 \u03b2-emitter + dosimetria MAA macroaggregated albumin Tc-99m + CNEN-NN-3.05; (c) abla\u00e7\u00e3o percut\u00e2nea<\/strong> com RFA radiofrequency ablation Boston Sci Cool-Tip + AngioDynamics RITA + microwave Covidien Emprint + AveCure HS + PEI alcooliza\u00e7\u00e3o etanol absoluto + crioabla\u00e7\u00e3o Galil Endocare; (d) TACE+TARE estrat\u00e9gias<\/strong> com BCLC B intermedi\u00e1rio primeira linha TACE + bridging para TX + downstaging Milan + bland embolization sem QT; (e) sist\u00eamico HCC IMbrave150 1L<\/strong> atezolizumab Tecentriq Roche 1.200mg + bevacizumab Avastin 15mg\/kg q3w + alternativa lenvatinib REFLECT + cabozantinib CELESTIAL 2L + durvalumab+tremelimumab HIMALAYA STRIDE + nivolumab+ipilimumab + iCCA futibatinib Lytgobi FGFR2+ivosidenib Tibsovo IDH1+pemigatinib Pemazyre+durvalumab Imfinzi TOPAZ-1 Lista C5.<\/p>\n

Cl\u00ednica com TACE+Y-90+sist\u00eamico madura escala TACE response 30-60%<\/strong> + escala Y-90 OS 12-26 meses<\/strong> + escala IMbrave150 OS 19,2 meses HCC<\/strong>. Conex\u00e3o com Y-90 brachy<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade hep\u00e1tica<\/h2>\n

Cl\u00ednica hep\u00e1tica s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.500-28.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica hep\u00e1tica A1 + A4 + TACE.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura cirurgia + TACE.<\/p>\n

Cl\u00ednica hep\u00e1tica 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa hep\u00e1tica + IMbrave150 OS 19,2m + Y-90 OS extens\u00e3o.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica hep\u00e1tica<\/h2>\n

O primeiro \u00e9 a subdimensionamento Y-90 SIRT CNEN-NN-3.05<\/strong>. Sem segrega\u00e7\u00e3o Y-90 SIR-Spheres+TheraSphere + decaimento + IPEN\/CNEN = n\u00e3o-conformidade radioativa + risco multa interdi\u00e7\u00e3o + zero prote\u00e7\u00e3o radiol\u00f3gica.<\/p>\n

O segundo \u00e9 a mistura A1 HCC + cirrose subjacente<\/strong>. Confunde rastreabilidade tumor + impossibilita Child-Pugh+MELD+BCLC estadiamento + risco TX inadequado.<\/p>\n

O terceiro \u00e9 a falta de protocolo Milan\/UCSF + downstaging<\/strong>. Sem rastreabilidade Milan 1\u00d75cm\/3\u00d73cm + UCSF 1\u00d76,5cm\/3\u00d74,5cm + downstaging TACE\/Y-90 = perda elegibilidade TX + sobrevida 5y reduzida 75%\u2192<40%.<\/p>\n

A regula\u00e7\u00e3o de PGRSS hep\u00e1tica no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer F\u00edgado<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS hep\u00e1tica 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 HCC 80% cirrose+VHB+VHC+\u00e1lcool+NASH+Child-Pugh A\/B\/C+AFP+iCCA 10% mass-forming+IDH1+FGFR2+KRAS+metast\u00e1tico colorretal+BCLC 0\/A\/B\/C\/D+CID C22, A4 hepatectomia anat\u00f4mica Couinaud I-VIII+ALPPS+PVE Onyx ev3+PVA+cyanoacrylate FLR 25-40%+TX Mayo Milan 1\u00d75cm\/3\u00d73cm+UCSF 1\u00d76,5cm\/3\u00d74,5cm+MELD 22+RLDLT+LLDLT+APOLT+dual-graft, C Y-90 SIR-Spheres Sirtex resin+TheraSphere Boston glass+MAA Tc-99m+CNEN-NN-3.05+IPEN, E TACE cTACE Lipiodol+doxo+DEB-TACE DC Bead Boston+HepaSphere+LC Bead+RFA Boston Cool-Tip+AngioDynamics RITA+microwave Emprint+AveCure+PEI etanol+crioabla\u00e7\u00e3o Galil+TIPS, sist\u00eamico atezolizumab Tecentriq+bevacizumab Avastin IMbrave150 OS 19,2m+lenvatinib REFLECT+sorafenib SHARP+cabozantinib CELESTIAL+durvalumab+tremelimumab HIMALAYA STRIDE+nivolumab+ipilimumab+futibatinib Lytgobi FGFR2 iCCA+pemigatinib Pemazyre+ivosidenib Tibsovo IDH1+durvalumab Imfinzi TOPAZ-1 Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia hep\u00e1tica: HCC + CCA + ressec\u00e7\u00e3o + TACE + Y-90. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3058,3057,3059],"class_list":["post-2226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-hcc","tag-hepatica","tag-tace"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2226"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2226\/revisions"}],"predecessor-version":[{"id":4336,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2226\/revisions\/4336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2224"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}